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Tumor necrosis factor alpha (TNF-a) and gamma interferon (IFN-g) are required for an effective immune
response to bacterial infection and these cytokines synergize in a variety of biological responses, including the
induction of cytokine, cell adhesion, and inducible nitrous oxide synthase gene expression. Typically, the
synergistic effect on gene expression is due to the independent activation of nuclear factor kB (NF-kB) by
TNF-a and of signal transducers and activators of transcription or IFN-regulatory factor 1 by IFNs, allowing
these transcription factors to bind their unique promoter sites. However, since activation of NF-kB by TNF-a
is often transient and would not activate long-term kB-dependent transcription effectively, we explored the
effects of IFN-g on TNF-a-induced NF-kB activity. IFN-g, which typically does not activate NF-kB, synergis-
tically enhanced TNF-a-induced NF-kB nuclear translocation via a mechanism that involves the induced
degradation of IkBb and that apparently requires tyrosine kinase activity in preneuronal cells but not in
endothelial cells. Correspondingly, cotreatment of cells with TNF-a and IFN-g leads to persistent activation
of NF-kB and to potent activation of kB-dependent gene expression, which may explain, at least in part, the
synergy observed between these cytokines, as well as their involvement in the generation of an effective immune
response.
Tumor necrosis factor alpha (TNF-a) is produced primarily
by macrophages and functions immunologically through tran-
scriptional up-regulation of genes encoding cell adhesion mol-
ecules required for the recruitment of inflammatory cells and
genes encoding important inflammatory cytokines such as
gamma interferon (IFN-g) (reviewed in references 8, 13, and
71). IFN-g is produced primarily by T cells and functions
immunologically by leading to transcriptional up-regulation of
class I and class II major histocompatibility complex (MHC)
genes in antigen-presenting cells, by stimulating macrophages,
and by inducing TNF-a secretion (reviewed in references 29
and 60). Data from in vivo experiments demonstrate that both
TNF-a and IFN-g are required for effective resistance to bac-
terial infection (7, 17, 24, 31, 32, 38, 39, 47, 54, 55, 61, 63). Also,
it has been shown that TNF-a and IFN-g play crucial roles in
the progression of the inflammatory response associated with
lipopolysaccharide-induced septic shock (29). Clearly, these
pleiotropic cytokines have significant physiologic importance
in regulating immune and inflammation processes.
TNF-a regulates the expression of genes which play critical
roles during immunologically mediated inflammation re-
sponses. Activation of the transcription factor nuclear factor
kappa B (NF-kB) by TNF-a is essential to elicit an effective
response, since many of the TNF-a-regulated genes contain
binding sites for NF-kB (reviewed in reference 6). The family
of mammalian NF-kB/Rel transcription factors consists of at
least five distinct members: c-Rel, NF-kB1 (p50), NF-kB2
(p52), RelA (p65), and RelB (reviewed in references 3, 6, 48,
52 and 72). Gene knockout studies reveal the importance of
NF-kB in several immunological pathways (9, 10, 18, 45, 70,
79); however, functional overlap may mask other important
roles for NF-kB. NF-kB is a homo- or heterodimer which
consists of various combinations of subunits. Classic NF-kB
exists as a p50/p65 heterodimer and typically resides in the
cytoplasm in an inactive form, bound by its inhibitor proteins
IkBa and IkBb (reviewed in reference 6). Upon TNF-a treat-
ment, signal transduction events cause phosphorylation, ubiq-
uitination, and degradation of IkB (15, 16, 19, 30), and the
subsequent release of NF-kB, which translocates into the nu-
cleus and regulates gene expression. IkBa has been studied
more extensively than IkBb; however, both inhibitor molecules
appear to interact with NF-kB through similar domains and
both preferentially bind p65- and c-Rel-containing dimers (76).
Recently, several differences between these two inhibitors have
been documented. First, IkBa is involved in the transient ac-
tivation of NF-kB while IkBb is targeted during the persistent
activation of NF-kB (43, 51, 75, 76). Second, the mitogens and
cytokines that activate NF-kB may favor the targeting of one
inhibitor protein over that of the other. For example, data
indicate that TNF-a preferentially targets IkBa, although
some reports indicate that IkBb can be targeted by TNF-a in
some cell types (43; see Discussion also). In contrast, interleu-
kin 1 (IL-1) targets both IkB molecules (43, 76; see Discussion
also).
Studies with a variety of human cell lines have demonstrated
that TNF-a and IFNs coregulate the expression of inflamma-
tion-associated genes such as MHC class I, intracellular cell
adhesion molecule 1 (ICAM-1), and vascular cell adhesion
molecule 1 in a synergistic manner (14, 26, 27, 41, 42, 57).
Specifically, TNF-a activates NF-kB, which binds kB elements
(reviewed in reference 6) while IFNs activate various IFN-
responsive factors which bind gamma-activated sites or IFN-
stimulated elements (reviewed in references 59 and 69) in the
promoters of target genes. Therefore, the synergistic induction
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of genes such as ICAM-1, vascular cell adhesion molecule 1,
and MHC class I is a result of the independent activation of
distinct transcription factors which engage unique promoter
elements (for example, see reference 57). Other reports of
transcriptional synergy between TNF-a and IFN-g include
studies on the genes that code for inducible nitric oxide syn-
thase (50, 74, 81), IL-8 (82), IL-6 (66), regulated on activation
normal T-expressed and -secreted chemokine (49), and inflam-
matory protein 10 (58), which are NF-kB regulated. Although
it is clear that the transcriptional synergy between TNF-a and
IFN-g involves NF-kB and IFN-induced factors, it is also likely
that sustained nuclear accumulation of NF-kB is required for
long-term transcriptional responses involving NF-kB-regulated
genes.
In this report, we describe the effects of IFN-g on the reg-
ulation of TNF-a-induced NF-kB activity. We demonstrate
that IFN-g, which on its own does not significantly induce
NF-kB, potentiates TNF-a-induced NF-kB nuclear transloca-
tion in a vascular endothelium cell line (EA.hy926) (28) and a
preneuron-like pheochromocytoma cell line (PC12) (34). The
mechanism involves the de novo degradation of IkBb, leading
to persistent NF-kB activation and to a potent kB-dependent
transcriptional response. In endothelial cells, the mechanism
also involves enhanced degradation of IkBa. Interestingly, the
combination of IFN-g and TNF-a at concentrations that alone
would not activate NF-kB, leads to significant nuclear accu-
mulation of this transcription factor. The protein tyrosine ki-
nase (PTK) inhibitor genistein can inhibit this synergy in PC12
cells, suggesting that PTK activity is required. However, inhi-
bition of PTK activity in endothelial cells augments the re-
sponse, which is consistent with a recent report that induced
PTK activity can limit NF-kB activation in some cells (73). The
synergistic activation of NF-kB by two critical proinflammatory
cytokines represents a mechanism by which NF-kB-induced
gene expression could be enhanced under inflammatory con-
ditions and may explain a critical aspect of the synergy between
TNF-a and IFN-g during an effective immune response.
MATERIALS AND METHODS
Cell culture and treatments. The preneuron-like rat adrenal pheochromocy-
toma cell line PC12 (CRL 1721; American Type Culture Collection, Rockville,
Md.) (34) was maintained in Dulbecco’s modified Eagle’s medium F12 supple-
mented with 10% fetal bovine serum and antibiotics. The human vascular en-
dothelial cell line EA.hy926 (gift from Cora-Jean S. Edgell, University of North
Carolina, Chapel Hill) (28) was maintained in Dulbecco’s modified Eagle’s
medium H supplemented with 10% fetal bovine serum, 13 hypoxanthine-ami-
nopterin-thymidine medium supplement (Boehringer Mannheim Biochemica,
Indianapolis, Ind.), and antibiotics. Cells were incubated for the times indicated
in Results with 0.025 to 10 ng of human recombinant TNF-a (Boehringer Mann-
heim) per ml, 50 to 100 U of human or rat recombinant IFN-g (Life Technol-
ogies, Gaithersburg, Md.) per ml, 100 U of human recombinant IFN-aA/D
(Biosource International, Camarillo, Calif.) per ml, 10 mg of cycloheximide
(CHX; Sigma Chemical Company, St. Louis, Mo.) per ml, and 100 mM genistein
(Sigma) or 50-ng/ml phorbol myristate acetate (PMA; Sigma).
Nuclear and cytoplasmic extracts. Cells were trypsinized, resuspended in
complete medium, and plated in 100-mm-diameter tissue culture plates (107
PC12 cells/plate or 2 3 106 EA.hy926 cells/plate) 16 to 18 h before treatment.
After treatment, nuclear and cytoplasmic extracts were made by using a modified
version of a previously described procedure (12). Cells were washed twice with
ice-cold phosphate-buffered saline, gently scraped from the plates, transferred to
microcentrifuge tubes, and lysed on ice in 3 pellet volumes of cytoplasmic
extraction buffer (10 mM HEPES [pH 7.6], 60 mM KCl, 1 mM EDTA, 0.1%
Nonidet P-40, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 2.5 mg
each of aprotinin, leupeptin, and pepstatin per ml). Nuclei were pelleted (200 3
g, 4°C, 5 min), and cytoplasmic supernatants were transferred to fresh tubes and
maintained on ice. Nuclei were washed gently with 100 ml of cytoplasmic extrac-
tion buffer without Nonidet P-40 and pelleted (200 3 g, 4°C, 5 min), and the
supernatants were discarded. Two pellet volumes of nuclear extraction buffer (20
mM Tris [pH 8.0], 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM
phenylmethylsulfonyl fluoride, 25% glycerol, 2.5 mg each of aprotinin, leupeptin,
and pepstatin per ml) were added, and the final salt concentration was adjusted
to ;400 mM with 2.5 M NaCl. Nuclear pellets were resuspended by vortexing,
and the nuclear lysates were maintained on ice for 10 min with occasional
vortexing. All cytoplasmic and nuclear extracts were cleared (16,000 3 g, 4°C, 10
min) and transferred to fresh tubes. Next, 100% gylcerol was added to the
cytoplasmic extracts to a final concentration of 20%, protein concentrations were
determined by the Bradford assay with the Bio-Rad protein assay dye reagent
(no. 500-0006; Bio-Rad Laboratories, Hercules, Calif.), and all extracts were
stored at 270°C.
EMSAs. For electrophoretic mobility shift assays (EMSAs), equal amounts of
nuclear extracts (5 or 10 mg of protein) were incubated for 15 min at room
temperature with a 32P-labeled probe containing a kB site from the class I MHC
promoter (59CAGGGCTGGGGATTCCCCATCTCCACAGTTTCACTTC39
[the NF-kB binding site is in bold face]) (4, 67) in binding buffer (10 mM Tris
[pH 7.7], 50 mM NaCl, 0.5 mM EDTA, 1 mM dithiothreitol, 10% glycerol) (37)
plus 2 mg of poly(dI-dC) z poly(dI-dC) (Pharmacia Biotech, Piscataway, N.J.).
Complexes were separated in 5% polyacrylamide gels in high-ionic-strength
Tris-glycine-EDTA buffer (25 mM Tris, 190 mM glycine, 1 mM EDTA), dried,
and autoradiographed. As a control in CHX experiments, nuclear extracts were
incubated with a 32P-labeled probe containing an early growth response protein
1 (EGR-1) binding site from the NF-kB1 (p50) promoter (59TCGACTCCCGC
CCCCGCTGCG39) (21).
For supershift experiments, 1 to 5 ml of rabbit polyclonal antibodies against the
p50 subunit (sc-114; Santa Cruz Biotechnology, Inc., Santa Cruz, Calif.) or the
p65 subunit (100-4165; Rockland, Gilbertsville, Pa.) of NF-kB was incubated
with nuclear extracts for 15 min prior to the addition of poly(dI-dC) z poly(dI-dC)
and a 32P-labeled probe and then analyzed on 5% polyacrylamide gels.
Western blot analysis. Equal amounts of cytoplasmic extracts (25 or 50 mg of
protein) were electrophoresed in 10% polyacrylamide–sodium dodecyl sulfate
gels and transferred to nitrocellulose membranes (Schleicher & Schuell, Keene,
N.H.). The upper half of each membrane was probed with an antibody specific
for IkBb (sc-945; Santa Cruz), and the lower half was probed with an antibody
specific for IkBa (100-4167C; Rockland). Specific proteins were visualized by
enhanced chemiluminescence (Amersham Life Science Inc., Cleveland, Ohio).
Transfection conditions and luciferase assays. Transient transfection of PC12
cells was accomplished by using 20 ml of Lipofectamine reagent (Life Technol-
ogies) per ml and a total of 6 mg of DNA for each sample. Plasmid pGEM7Zf(1)
was used to equalize the amount of DNA transfected in each set of samples. The
MHC-NF-kBLuc plasmid contains three tandem repeats of the kB site from the
MHC class I enhancer, and the MHCmut-NF-kBLuc plasmid contains three
copies of the mutated enhancer sequence (5) cloned into a luciferase expression
vector. (Luciferase expression vectors were a gift from Bill Sugden, University of
Wisconsin, Madison.) The pCMVIkBa expression plasmid was described previ-
ously (11). The IkBa constitutive repressor expression plasmid IkBaS32/36A, in
which serines 32 and 36 were mutated to alanines was a gift from Dean Ballard
(Vanderbilt University, Nashville, Tenn.) (68). In general, 7 3 106 PC12 cells
were plated in 60-mm-diameter tissue culture plates 16 to 18 h before transfec-
tion and fed with fresh, complete medium 1 to 2 h before transfection. Lipo-
fectamine-DNA complexes were allowed to form for 30 min in serum-free
medium before being added to the cells which were washed out of complete
medium and into 2 ml of serum-free medium just prior to the addition of
complexes. Cells were incubated with the complexes for 7 to 8 h, the medium was
replaced with medium containing 0.5% serum, and 8 h of cytokine treatment
began 36 h after the medium change. Cells were washed twice with ice-cold
phosphate-buffered saline, collected, resuspended in 2 pellet volumes of 0.25 M
Tris (pH 7.5), and subjected to three freeze-thaw cycles. Samples were cleared
(16,000 3 g, 4°C, 10 min), and protein concentrations were determined with the
Bio-Rad protein assay dye reagent. Luciferase assays were performed in dupli-
cate on equal amounts of protein (25 or 50 mg) with 200 mM D-luciferin as the
substrate (Sigma), and relative light units were determined with an AutoLumat
LB953 luminometer (Berthold Analytical Instruments, Inc., Nashua, N.H.).
RESULTS
TNF-a and IFN-g synergistically activate NF-kB nuclear
translocation. Synergy between TNF-a and IFN-g has been
reported in numerous cell types; therefore, we chose two cell
lines for our studies. PC12 cells are rat preneuron-like pheo-
chromocytoma cells (34) that exhibit rapid and transient acti-
vation of NF-kB and provide a model for the potential involve-
ment of NF-kB in neurological disorders (35, 44). EA.hy926
cells are immortalized human endothelial cells which exhibit
many normal endothelial responses (28). These cells are par-
ticularly useful for studies on the role of NF-kB during immu-
nologically induced inflammation. To determine the effect of
IFN-g on TNF-a-induced NF-kB DNA binding activity in
vitro, the cell lines were treated with each cytokine alone or
with both cytokines simultaneously and nuclear extracts were
analyzed by EMSA (Fig. 1). As expected, there was very little
binding to a consensus kB site with nuclear extracts from
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untreated PC12 cells (Fig. 1A, lane 1) or untreated EA.hy926
cells (Fig. 1B, lane 1). Upon treatment for 30 min with TNF-a
alone, one major complex (p50/p65; see below) formed in both
cell lines. In PC12 cells, this complex disappeared by 1 h and
reappeared at extremely low levels by 4.5 h (Fig. 1A, lanes 2 to
5). In EA.hy926 cells, the binding of this complex slowly de-
creased over time (Fig. 1B, lanes 2 to 5) but did not return to
basal levels until greater than 12 h after treatment (data not
shown). As anticipated, treatment with IFN-g alone did not
induce binding to the NF-kB-specific probe in either cell line
(Fig. 1A and B, lanes 6 to 9). Cotreatment with TNF-a and
IFN-g elicited a striking cooperative effect on kB-specific bind-
ing activity in both cell lines. In PC12 cells, the major NF-kB
complex exhibited a large increase in binding by 4.5 h of co-
treatment which remained elevated for at least another 4.5 h
(Fig. 1A, lanes 10 to 13). This second peak of binding activity
was consistently greater than the binding observed after 30 min
of cotreatment and significantly greater than the binding ob-
served after 4.5 h of treatment with TNF-a alone (compare
lanes 4, 10 and 12). In EA.hy926 cells, cotreatment with TNF-a
and IFN-g caused the major DNA binding complex to form
earlier (within 15 min) and produced greater binding activity
than did treatment with TNF-a alone (Fig. 1B, compare lanes
2 through 5 to lanes 10 through 13). The binding activity was at
least fourfold higher and remained elevated longer in co-
treated EA.hy926 cells than in cells treated with TNF-a alone.
Although the NF-kB activation profiles of PC12 and EA.hy926
cells differ in regard to the timing and amount of binding, it is
clear that TNF-a and IFN-g exert a synergistic, not an additive,
effect on the induction of binding to a kB-specific probe. The
concentration of TNF-a was critical for the synergy between
TNF-a and IFN-g in EA.hy926 cells. For example, at TNF-a
concentrations greater than 1 ng/ml, the synergy produced by
cotreatment was obscured because the NF-kB binding activity
was already maximal due to TNF-a alone. Of great interest
relative to issues of inflammation and immune responses was
the finding that a low concentration of TNF-a, which does not
significantly activate NF-kB by itself, can act synergistically
with IFN-g to produce strong binding activity (Fig. 1B, lanes 14
to 17).
To verify that the induced complexes contained NF-kB and
to identify the subunits in the complexes, antibody supershift
experiments were performed on nuclear extracts from PC12
and EA.hy926 cells treated for 30 min with TNF-a by using
antibodies specific for the p50 and p65 NF-kB subunits (Fig.
1C). In EA.hy926 cells, the p50-specific antibody shifted com-
plex C2 (lane 2) and the p65 antibody completely shifted com-
plexes C1 and C2 (lane 3). In PC12 cells, the p50-specific
antibody repressed the formation of complex C2 and com-
pletely shifted complex C3 (lane 5) while the p65-specific an-
tibody completely shifted complexes C1 and C2 (lane 6). These
data indicate that the major induced complex in both cell lines
is the p50/p65 heterodimer (C2) and the minor induced com-
plexes are most likely p50/p50 homodimers (C3) and either
p65/c-Rel or p65/p52 heterodimers (C1). Since c-Rel is a com-
ponent of activated NF-kB in some cells, we tested whether the
mobilization of c-Rel changes during TNF-a–IFN-g costimu-
lation. Our data indicate that c-Rel activation in response to
TNF-a–IFN-g cotreatment is not appreciably different from
that caused by TNF-a alone in our two experimental cell lines
(20a).
Synergistic activation of NF-kB by TNF-a and IFN-g in-
volves enhanced IkBa degradation and induced IkBb degra-
dation. Normally, NF-kB is sequestered in the cytoplasm by its
inhibitory proteins, which are collectively referred to as IkBs.
A variety of stimuli promote the degradation of specific IkB
proteins, which results in the release and nuclear translocation
of NF-kB (reviewed in reference 6). To elucidate the mecha-
FIG. 1. Synergistic activation of NF-kB by cotreatment with TNF-a and IFN-g. (A) EMSA of equal amounts of protein from PC12 cell nuclear extracts using a
probe containing a consensus NF-kB binding site. The time and treatment are indicated above each lane (UT is untreated). The TNF-a and IFN-g concentrations were
10 ng/ml and 100 U/ml, respectively. Arrows indicate the major NF-kB-specific band (p50/p65), a nonspecific band (n.s.), and the free probe. (B) EMSA of equal
amounts of protein from EA.hy926 cell nuclear extracts. The probe used and labeling of lanes are the same as in panel A. The TNF-a and IFN-g concentrations were
0.1 ng/ml and 100 U/ml, respectively, for lanes 1 to 13 and 25 pg/ml and 100 U/ml, respectively, for lanes 14 to 17. (C) Identification of NF-kB complexes. Nuclear
extracts were incubated with antibodies specific for individual NF-kB subunits, and complexes were resolved by EMSA. Cells were left untreated or were treated for
0.5 h with TNF-a at 0.1 (EA.hy926 cells) or 10 (PC12 cells) ng/ml. Antibodies (Ab) are indicated at the top of each lane, and arrows indicate all NF-kB-specific bands
(C1, C2, and C3) and a nonspecific band. Supershifted complexes are indicated by asterisks.
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nism by which TNF-a and IFN-g costimulate NF-kB, we in-
vestigated the effects of these cytokines on IkBa and IkBb
degradation. Western blot analyses examining the levels of the
IkBa and IkBb proteins were performed on cytoplasmic ex-
tracts collected at the same time as the nuclear extracts that
were analyzed for Fig. 1. In PC12 cells, 30 min of TNF-a
treatment reduced IkBa protein levels but did not reduce
IkBb (Fig. 2A, compare lanes 1 and 2). IFN-g treatment alone
did not cause degradation of either IkB protein (lanes 6 to 9).
Interestingly, TNF-a–IFN-g cotreatment caused extensive
degradation of IkBb by 4.5 h (lane 12). Similarly, in EA.hy926
cells, 15 to 30 min of TNF-a treatment reduced IkBa protein
levels but did not reduce IkBb levels (Fig. 2B, compare lanes
1 through 3) and IFN-g treatment alone did not decrease the
level of either IkB protein (lanes 6 through 9). TNF-a–IFN-g
cotreatment caused a greater loss of IkBa protein than did
TNF-a treatment alone (compare lanes 3 and 11) and exten-
sive degradation of IkBb within 1 h (lanes 12 and 13). In both
cell lines, IkBa was resynthesized and returned to basal levels
after TNF-a treatment alone or TNF-a–IFN-g cotreatment
(Fig. 2A and B, lanes 2 to 5 and 10 to 13); however, IkBb
protein levels remained reduced for at least 5 h (Fig. 2A and B,
lane 13). The expression of IkBa is transcriptionally regulated
by NF-kB (reviewed in reference 6); however, the expression
of IkBb is not (76). This may explain the differential reappear-
ance of these two inhibitors. Peptide competitions verified that
the bands detected by immunoblotting were the proteins of
interest (data not shown). In summary, TNF-a–IFN-g cotreat-
ment enhanced the degradation of IkBa compared to TNF-a
treatment alone and induced the degradation of IkBb.
Comparing the NF-kB activation profiles shown in Fig. 1A
and B to the degradation patterns of IkBa and IkBb shown in
Fig. 2A and B indicates that the TNF-a–IFN-g-induced syn-
ergistic activation of NF-kB corresponds precisely to the en-
hanced degradation of IkBa and de novo degradation of IkBb.
Therefore, it is likely that the increased amount of NF-kB
detected in nuclear extracts from cells cotreated with TNF-a
and IFN-g, compared with those treated with TNF-a alone,
was due to the release of NF-kB molecules from both inhibitor
proteins as they were degraded.
IFN-a also potentiates TNF-a-induced NF-kB activation.
There are three distinct classes of IFNs which fall into two
different categories based on their receptors and biological
activities. IFN-a and IFN-b are type I interferons, whereas
IFN-g is a type II interferon (29, 60). To determine if the
synergy between TNF-a and IFN-g during NF-kB activation is
unique to IFN-g or if this synergy is common to both types of
IFNs, we repeated the experiments described in Fig. 1B and 2B
with EA.hy926 cells, comparing IFN-a to IFN-g. Upon treat-
ment with TNF-a alone, one major NF-kB complex formed
(Fig. 3, lanes 2 to 5) and, as expected, treatment with IFN-g or
IFN-a alone did not activate NF-kB (data not shown). Co-
treatment with TNF-a and IFN-a elicited the same striking
cooperative effect on kB-specific binding as that obtained by
cotreatment with TNF-a and IFN-g (compare lanes 6 through
9 to lanes 10 through 13). The results were indistinguishable in
that both IFNs synergized with TNF-a to induce NF-kB to
similar levels in a similar time frame. The effects on IkB pro-
tein levels were analogous also. The degradation of IkBa was
enhanced compared to that caused by TNF-a treatment alone,
and de novo degradation of IkBb occurred regardless of
whether IFN-a or IFN-g was used in combination with TNF-a
(data not shown). As described earlier for TNF-a–IFN-g co-
treatment, the NF-kB activation profile observed with TNF-
a–IFN-a cotreatment corresponds precisely to the degradation
of IkBa and IkBb.
Protein synthesis is not required for the synergistic activa-
tion of NF-kB by TNF-a and IFN-g. To rule out the possibility
that the TNF-a–IFN-g synergy depends on an increase in
TNF-a or IFN-g receptor synthesis and to determine if the
signal transduction molecules required for coactivation of
NF-kB pre-exist in cells, PC12 cells were pretreated with the
protein synthesis inhibitor CHX and then treated with TNF-a
and/or IFN-g. As previously documented, the induction of
NF-kB DNA binding activity by TNF-a alone does not require
protein synthesis (3, 48, 52, 72) (Fig. 4, compare lanes 3 and 4).
Figure 4, lanes 7 to 10, indicates that CHX did not inhibit
synergistic activation of NF-kB but actually enhanced its bind-
FIG. 2. Cotreatment with TNF-a and IFN-g enhances IkBa degradation and
induces IkBb degradation. (A) Western analyses of equal amounts of protein
from PC12 cell cytoplasmic extracts using polyclonal antibodies specific for IkBa
or IkBb. The time and treatment are indicated above each lane (UT is untreat-
ed). The TNF-a and IFN-g concentrations were 10 ng/ml and 100 U/ml, respec-
tively. Arrows indicate each specific IkB protein and nonspecific bands (n.s.). (B)
Western analyses of equal amounts of protein from EA.hy926 cell cytoplasmic
extracts. The antibodies used and labeling of lanes are the same as in panel A.
The TNF-a and IFN-g concentrations were 0.1 ng/ml and 100 U/ml, respectively.
Asterisks highlight the synergistic effects of TNF-a–IFN-g costimulation.
FIG. 3. Synergistic activation of NF-kB by cotreatment with TNF-a and
IFN-a. EMSA of equal amounts of protein from EA.hy926 cell nuclear extracts
using a probe containing a consensus NF-kB binding site. The time and treat-
ment are indicated above each lane (UT is untreated). The TNF-a, IFN-g, and
IFN-a concentrations were 0.05 ng/ml, 100 U/ml, and 100 U/ml, respectively.
Arrows indicate the major NF-kB-specific band (p50/p65) and a nonspecific band
(n.s.).
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ing slightly. This enhanced binding (over synergistic levels) was
most likely due to the lack of IkBa resynthesis in the presence
of CHX (data not shown). Western analyses also demonstrated
that IkBb was degraded upon cotreatment in the presence or
absence of CHX (data not shown); therefore, the preservation
of the synergistic activation of NF-kB in the presence of CHX
was a result of the degradation of IkBb and was not due to the
lack of IkBa resynthesis alone. To verify that CHX inhibited
protein synthesis adequately in these experiments, PMA acti-
vation of EGR-1 was used as a positive control since this
transcription factor requires protein synthesis for activation
(33). Pretreatment with CHX inhibited the binding of EGR-1
to its consensus site, which clearly demonstrated the integrity
of the CHX reagent (Fig. 4, lanes 11 and 12). Similar experi-
ments with CHX pretreatment of EA.hy926 cells followed by
cotreatment with TNF-a and IFN-g yielded results comparable
to those obtained with PC12 cells (data not shown). In sum-
mary, our data show that protein synthesis was not required for
synergistic activation of NF-kB by TNF-a–IFN-g cotreatment.
Genistein inhibits TNF-a–IFN-g-induced NF-kB activation
in PC12 cells and enhances activation in EA.hy926 cells. IFNs
are known to induce the activation of signal transducers and
activators of transcription through the PTK activity of the
Janus family of protein kinases (JAKs) (25, 40, 69); therefore,
we tested whether PTK activity is required for TNF-a–IFN-g
synergy in NF-kB activation. PC12 and EA.hy926 cells were
pretreated with the PTK inhibitor genistein for 1 h before
TNF-a–IFN-g cotreatment, and then nuclear extracts were
analyzed by EMSA. Figure 5A illustrates that in PC12 cells, the
coactivation of NF-kB is completely blocked by genistein, in-
dicating that PTK activity is required for this synergistic re-
sponse (compare lane 3 to lane 4 and lane 5 to lane 6). In PC12
cells, the PTK activity is most likely controlled by IFN-g since
NF-kB binding that is attributed to activation by TNF-a alone
is not blocked by genistein (data not shown). Conversely, in
EA.hy926 cells, genistein enhances NF-kB synergistic activa-
tion, as revealed by the increase in NF-kB binding in the
presence of this PTK inhibitor (Fig. 5B, compare lane 3 to lane
4 and lane 5 to lane 6). Genistein alone had no effect on the
basal level of NF-kB activity in either cell line (Fig. 5A and B,
compare lanes 1 and 2). These data indicate that regulatory
mechanisms involved in the synergy of TNF-a and IFN-g rel-
ative to NF-kB activation are likely to involve distinct mecha-
nisms in PC12 and endothelial cells (see Discussion).
TNF-a and IFN-g synergistically activate kB-dependent
transcription. To test whether the synergistic activation of
NF-kB leads to enhanced NF-kB-dependent transcriptional
responses, we examined the ability of TNF-a and IFN-g to
costimulate kB-dependent reporter gene expression. PC12
cells were transiently transfected with a luciferase reporter
construct containing three kB sites cloned in tandem in front
of the minimal luciferase promoter (MHC-NF-kBLuc) or
with a similar construct in which the kB sites were mutated
(MHCmut-NF-kBLuc). The cells were treated with TNF-a
and/or IFN-g for 8 h, and lysates were assayed for luciferase
activity. The wild-type kB sites conferred a 4-fold induction
upon treatment with TNF-a, a 3-fold induction upon treat-
FIG. 4. Protein synthesis is not required for synergistic activation of NF-kB
by TNF-a and IFN-g. EMSA of nuclear extracts from PC12 cells pretreated for
1 h with 10-mg/ml of CHX. The time and treatment are indicated above each lane
(UT is untreated). The TNF-a, IFN-g, and PMA concentrations were 10 ng/ml,
100 U/ml, and 50 ng/ml, respectively. Arrows indicate the major NF-kB-specific
band (p50/p65), the EGR-1-specific band, and a nonspecific band (n.s.).
FIG. 5. The PTK inhibitor genistein affects TNF-a–IFN-g-induced NF-kB
activation. (A) EMSA of nuclear extracts from PC12 cells pretreated for 1 h with
100 mM genistein. The time and treatment are indicated above each lane (UT is
untreated). The TNF-a and IFN-g concentrations were 1 ng/ml and 100 U/ml,
respectively. Arrows indicate the major NF-kB-specific band (p50/p65) and a
nonspecific band (n.s.). (B) EMSA of nuclear extracts from EA.hy926 cells
pretreated for 1 h with 100 mM genistein. The time and treatment are indicated
above each lane. The TNF-a and IFN-g concentrations were 0.05 ng/ml and 100
U/ml, respectively.
FIG. 6. Synergistic activation of kB-dependent reporter gene expression by
TNF-a–IFN-g cotreatment. PC12 cells transfected with equal amounts of a
kB-dependent luciferase reporter construct (MHC-NF-kBLuc) or its mutated
counterpart (MHCmut-NF-kBLuc) were treated with TNF-a at 5 ng/ml, IFN-g
at 50 U/ml, or a combination of both for 8 h. Lysates were assayed in duplicate
for luciferase activity, and fold activation was determined by dividing the number
of relative light units from treated samples by the number of relative light units
from untreated (UT) samples. The data shown are averages of three indepen-
dent experiments, and the standard errors of the means are indicated by error
bars.
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ment with IFN-g, and a potent 25-fold induction upon TNF-
a–IFN-g cotreatment compared to the basal activity of this
expression construct in untreated cells (Fig. 6).
This synergistic induction of gene expression was completely
abolished in transfections using the reporter construct contain-
ing mutated kB sites (Fig. 6), and cotransfections with a wild-
type IkBa (11) or an IkBa constitutive repressor expression
vector (68) inhibited the induction of MHC-NF-kBLuc by at
least 50 and 95%, respectively (data not shown). Additionally,
we have made two PC12 cell lines, one which stably expresses
MHC-NF-kBLuc and one which stably expresses MHCmut-
NF-kBLuc. The stable cell line expressing the wild-type plas-
mid exhibits a 29-fold induction of luciferase activity by TNF-a
treatment alone, a 3-fold induction by IFN-g alone, and a
synergistic 68-fold induction by TNF-a–IFN-g cotreatment
(data not shown). The stable cell line expressing the plasmid
containing mutated kB sites does not exhibit an increase in
luciferase activity upon cytokine treatment (data not shown).
Transfection experiments have not been repeated with
EA.hy926 cells due to their loss of viability during transfection
procedures.
The synergistic activation of NF-kB by TNF-a and IFN-g
also enhances the expression of endogenous genes that contain
kB sites in their promoters. Northern analysis of PC12 cells
indicates a synergistic increase in the abundance of IkBa
mRNA upon cotreatment with TNF-a and IFN-g compared
with treatment with TNF-a alone (data not shown). In sum-
mary, our data indicate that the synergistic activation of NF-kB
by TNF-a and IFN-g leads to a potent synergistic effect on
NF-kB-dependent transcription.
DISCUSSION
The cytokines TNF-a and IFN-g function cooperatively dur-
ing many biological responses. For example, they have syner-
gistic cytotoxic effects on tumor cells, they synergistically co-
activate gene expression, they function together to elicit an
effective immune response, they increase the activation of lym-
phocytes, and they induce the differentiation of neuroblastoma
cells (reviewed in references 29 and 71). Furthermore, TNF-a
and IFN-g are intimately involved in the inflammation re-
sponse during septic shock (29). There are several possible
mechanisms by which these cytokines may collaborate. In some
instances, their cooperativity may be explained by the IFN-g-
induced up-regulation of TNF-a receptors (1, 64, 78) or vice
versa (46, 65). Also, TNF-a–IFN-g synergy may be explained
by the independent activation of distinct transcription factors
(e.g., NF-kB, IFN-regulatory factor 1, and signal transducers
and activators of transcription) which bind to unique promoter
sites and synergistically regulate genes containing TNF-a- and
IFN-responsive elements in their promoters. In addition, Drew
et al. showed that NF-kB and IFN-regulatory factor 1 can
physically interact (27). The transcription factor NF-kB is
clearly important during an immune response, since it controls
transcription of a variety of genes required for an effective
response (3, 6, 48, 52, 72). Since NF-kB activation can be
relatively transient in response to TNF-a stimulation, we have
examined the potential for IFNs to enhance TNF-a-induced
NF-kB activation. We investigated two distinct cell types to
understand the potentially ubiquitous nature of the effects of
TNF-a–IFN-g cotreatment on the activation of NF-kB. We
chose EA.hy926 cells since endothelial cells play a critical role
during immunologically induced inflammatory responses by
up-regulating the expression of kB-dependent cell adhesion
molecules and by producing cytokines and growth factors (22,
23, 62). We selected PC12 cells since it has been proposed that
activation of NF-kB in the nervous system may play a role in
the progression of neurodegenerative diseases such as Alzhei-
mer’s disease, Down’s syndrome, Parkinson’s disease, and
amyotrophic lateral sclerosis (44).
Our data clearly show that IFNs can strongly potentiate the
ability of TNF-a to induce NF-kB nuclear translocation and
stimulate kB-dependent transcription (Fig. 1, 3, and 6). A
major component of this synergistic activation is a mechanistic
switch from the degradation of IkBa to the targeted degrada-
tion of IkBb, which leads to persistent activation of NF-kB. In
our model (Fig. 7), TNF-a and IFN-g bind to their respective
receptors and activate individual signal transduction pathways.
TNF-a, by itself, targets IkBa for degradation, allowing nu-
clear translocation of NF-kB. TNF-a, in the presence of signals
originating from the interaction of IFN-g with its receptor,
targets both IkBa and IkBb for degradation. This increases the
amount of NF-kB that is free to translocate and therefore
synergistically increases the amount of kB-dependent gene ex-
pression. Recently, Harhaj et al. demonstrated that CD28 and
PMA can costimulate NF-kB activity during T-cell activation
by inducing the rapid degradation of both IkBa and IkBb (36).
Although our model for TNF-a–IFN-g costimulation is similar
to these findings, there is a major fundamental difference. In
our model, one stimulus (IFN-g) does not activate NF-kB by
itself while the other stimulus (TNF-a) does. In the T-cell
activation system, each stimulus (CD28 or PMA) activates
NF-kB by itself.
TNF-a is a well-known initiator of NF-kB nuclear translo-
cation controlled through the targeted phosphorylation and
subsequent degradation of IkBa. The distinct regulatory com-
ponents of the signal transduction pathway(s) involved in this
response have not been defined clearly. The induced phos-
phorylation of IkBa on serines 32 and 36 leads to ubiquitina-
tion and subsequent degradation via a proteasome-mediated
mechanism (15, 16, 19). IkBb is presumed to be regulated by
phosphorylation on two serines in analogous positions; how-
ever, IkBb is more resistant to targeting by TNF-a (76, 80).
FIG. 7. Model of the synergistic activation of NF-kB by TNF-a and IFN-g.
NF-kB is sequestered in the cytoplasm by IkBa and IkBb. Upon treatment with
TNF-a alone, IkBa is modified and degraded, releasing NF-kB, which is free to
translocate into the nucleus and bind to kB sites in target genes. Upon treatment
with IFN-g alone, neither IkB molecule is affected and therefore no NF-kB is
released. Upon cotreatment with TNF-a and IFN-g, IkBa degradation is en-
hanced and de novo IkBb degradation occurs. This leads to persistent activation
of NF-kB (74) and to a synergistic increase in kB-dependent gene expression.
The question mark indicates that the relationship between treatment with TNF-a
alone and IkBb degradation has not been established definitively. This is dis-
cussed in the text.
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Additionally, when IkBb is targeted, it is usually degraded with
slower kinetics than IkBa (76). The basis of these phenomena
is not understood; thus, it is not known whether IkBb is reg-
ulated by an inducible kinase that is distinct from the kinase
that regulates IkBa (20).
Although there is a report that IFN-g may cause low levels
of NF-kB activity in peritoneal macrophages after several
hours of treatment (56), IFNs do not generally activate NF-kB.
In our experiments, IFN-g by itself did not significantly acti-
vate NF-kB. How does TNF-a–IFN-g cotreatment lead to
enhanced activation of NF-kB? First, we show that the syner-
gistic induction of NF-kB involves a switch from targeting
IkBa for degradation to targeting IkBb. Although both PC12
and EA.hy926 cells exhibit enhanced activation of NF-kB and
both show the IkBa-to-IkBb switch mechanism, there are cell
type-specific differences in response to TNF-a–IFN-g cotreat-
ment. In EA.hy926 cells, cytokine cotreatment enhances IkBa
degradation and targets IkBb for degradation, which amplifies
NF-kB activation. The earlier and stronger degradation of
IkBa which leads to enhanced activation of NF-kB in
EA.hy926 cells was not observed in PC12 cells. Second, we
show that the synergistic activation of NF-kB is independent of
protein synthesis; therefore, this activation cannot be ex-
plained by increased synthesis of TNF-a or IFN-g receptors.
This suggests that the activation of signal transduction path-
ways initiated by IFN-g control the response. Third, we impli-
cate PTK activity in the synergistic activation of NF-kB by
TNF-a–IFN-g cotreatment in PC12 cells.
Of particular interest were the different cellular responses to
the PTK inhibitor genistein. Genistein was originally charac-
terized and is commonly used as a PTK inhibitor (2), although
it has other biological activities (reviewed in reference 77).
Genistein blocked the IkBb-dependent mechanism in PC12
cells and, as predicted, blocked the second wave of the NF-kB
biphasic response but did not block the early IkBa-controlled
response. This implies that a genistein-sensitive PTK is not
involved in the ability of TNF-a to lead to the phosphorylation
of IkBa but may be required for IFN-g to induce IkBb phos-
phorylation. Although there are several possible mechanisms,
it is conceivable that a member of the IFN-sensitive JAKs
(which is sensitive to genistein) could be a component of the
signaling pathway in PC12 cells. Curiously, the TNF-a–IFN-g-
induced NF-kB activity in EA.hy926 cells was not blocked by
genistein but was enhanced under these conditions. Consistent
with our data, Tiisala et al. demonstrated that genistein en-
hances the TNF-a-induced cell surface expression of the kB-
dependent gene for ICAM-1 in EA.hy926 cells (77). This in-
dicates a different mechanism of control in these cells, in which
PTK activity may normally inhibit the synergistic induction
process. Recently, Singh and coworkers showed that tyrosine
phosphorylation of IkBa functions negatively to feed back and
abrogate the TNF-a activation of NF-kB; therefore, this mech-
anism may explain the results obtained with EA.hy926 cells
(73). Alternatively, the signal transduction cascade initiated by
IFN-g may be negatively controlled by tyrosine kinase activity.
In both of these scenarios, IFN-g may potentiate the activity of
a single IkB kinase to induce phosphorylation of IkBa and
IkBb. This would support a model whereby the “strength” of
the signal directed to a single kinase determines whether IkBb
is targeted for degradation. The strength of the signal could
depend on the concentration or specific activity of the induc-
er(s), as well as the cell type or particular inducer(s) used. For
instance, the initial characterization of NF-kB inducers which
target IkBb demonstrated that neither PMA treatment of
70Z/3 pre-B cells nor TNF-a treatment of Jurkat T cells in-
duced IkBb degradation (76). However, more recent studies
show that both PMA and TNF-a target IkBb in human um-
bilical vein endothelial cells (43). Thus, cell type-specific re-
sponses may control whether or not IkBb is targeted. In an
alternate model, a distinct IkBb kinase may exist and, by an
unknown mechanism, IFN-g may lead to the activation of this
kinase, but only in the presence of signals initiated by TNF-a.
These questions can be answered only when more is revealed
about the nature and identity of the IkB kinase(s). In either
model, the targeting of IkBb leads to persistent activation of
NF-kB. Suyang and colleagues have described a mechanism in
which IkBb can function either as an inhibitor (under non-
stimulated conditions) or as a chaperonelike protein (under
stimulated conditions) which protects NF-kB from the inhibi-
tory properties of IkBa (75). The latter mechanism is ex-
plained by the differential phosphorylation of IkBb, leading to
inhibitory or protective functions.
The biological implications for TNF-a–IFN-g synergies are
extensive and may underlie many important aspects of immune
function and inflammatory diseases. Monocytes and macro-
phages are the primary sources of TNF-a under conditions of
inflammation (reviewed in reference 71), and T cells are the
primary source of IFN-g in response to immunological stimuli
(reviewed in reference 29). Due to the interactions between
these cell types, there is extensive opportunity for TNF-a–
IFN-g synergy to occur. Under these conditions, enhanced
NF-kB activation would be important in regulating a number
of immunologically significant genes, such as those encoding
cell adhesion molecules or cytokines. Since the genes coding
for TNF-a and IFN-g may be regulated by NF-kB (reviewed in
reference 6), there is the opportunity for enhanced production
of both cytokines under these synergistic conditions. Of par-
ticular interest is the observation (Fig. 1B) that suboptimal
levels of TNF-a can activate NF-kB in the presence of IFN-g,
indicating that IFN-g can make cells more susceptible to the
stimulatory effects of TNF-a. Additionally, IFN-g may sensi-
tize cells to other inducers of NF-kB. Consistent with this idea,
Murphy et al. have reported that IFN-g augments the ability of
lipopolysaccharide to activate NF-kB and to induce IL-12 p40
gene expression (53). Understanding the mechanisms whereby
IFNs signal to modulate NF-kB functional activity is essential
for understanding the basic components of immunological and
inflammatory processes. The ability to repress such a pathway
would have important implications for the inhibition of chronic
inflammatory diseases.
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